Keywords
Advanced gastric cancer
Ovarian cancer
Ascites
Submitted : 2024-10-28
Accepted : 2024-11-12
Published : 2024-11-27
Abstract
Objective: To observe the time of ascites disappearance, time to ascites recurrence, improvement rate in quality of life, and the effective rate of ascites treatment in patients with advanced gastric and ovarian cancer with ascites following hypotonic hyperthermic intraperitoneal chemotherapy. Methods: Forty patients with advanced gastric and ovarian cancer with ascites, treated in our hospital from January 2021 to August 2024, were selected as research subjects. They were divided into a treatment group and a reference group using a random number table method. The treatment group received hypotonic hyperthermic intraperitoneal chemotherapy, while the reference group received conventional treatment. The treatment effects of the two groups were compared. Results: In the treatment group, the ascite disappearance time was (6.13 ± 1.32) days, and the recurrence time was (22.58 ± 8.21) months. The ascite disappearance time was significantly shorter than that of the reference group, and the ascite recurrence time was significantly longer. Both P-values were less than 0.05, indicating statistical significance. The effective rate of quality of life improvement was 95%, with only 1 patient showing a decrease in quality of life. The effective rate of ascites treatment was 95%, with only 1 patient showing an increase in ascites. Both the quality of life improvement rate and the effective rate of ascites treatment were significantly higher than those of the reference group, with P-values of 0.037 and 0.018, respectively, indicating statistical significance. Conclusion: For patients with advanced gastric and ovarian cancer with ascites, hypotonic hyperthermic intraperitoneal chemotherapy can accelerate ascites disappearance, prolong the time to recurrence, and significantly improve both the quality of life improvement rate and the effective rate of ascites treatment.
References
Sheng W, Song M, Liu P, et al., 2023, Influencing Factors of Pulmonary Complications After Cytoreductive Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy. J Clin Anesthesiol, 39(10): 1036–1039.
Wang J, Liu H, Wang S, 2023, Sequential Hyperthermic Intraperitoneal Chemotherapy After Hepatocellular Carcinoma Resection for Spontaneous Rupture and Bleeding of Liver Cancer. Chin J Gen Surg, 32(7): 1014–1022.
Chen T, Jiang X, Wu J, et al. Safety Analysis of Radical Resection Combined With Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Gastric Cancer. Mod Oncol, 31(5): 869–874.
Yang Z, Su Y, Yang R, et al., 2023, Analysis of Complications and Risk Factors of Cytoreductive Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Malignant Peritoneal Mesothelioma. Chin J Clin Oncol, 50(13): 661–666.
Chang X, Wang H, Wang J, et al., 2024, Application of Cytoreductive Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Recurrent Nephroblastoma. J Clin Pediatr Surg, 23(5): 464–468.
Chinese Anti-Cancer Association Cervical Cancer Professional Committee, Li J, Lin Z, 2024, Expert Consensus on Clinical Drug Application of Hyperthermic Intraperitoneal Chemotherapy for Gynecologic Tumors (2024 Edition). Chin J Pract Gynecol Obstet, 40(1): 62–67.
Liu X, Zhou J, Gao Y, et al., 2023, Nursing Care of a Patient With Lymphatic Leakage After Total Gastrectomy Combined With Hyperthermic Intraperitoneal Chemotherapy. Nurs Res, 37(13): 2467–2470.
Huang C, Shi H, Zhang H, et al., 2023, Prognostic Analysis and Safety Evaluation of Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Gastric Cancer Patients With Peritoneal Metastasis. Chin J Clin Oncol, 50(14): 703–707.